Saturday 17 October 2026
Export IBRX’s income statement to Excel — free account
ImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024. In the quarter to June 2026, revenue grew 93.9%, EPS fell 120.0%, free cash flow grew 13.4% and total debt rose 57.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
9.18
0.82
−8.20%
Follow IBRX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 3 | 3 | 3 | 1 | 3 | 3 | 4 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
16.08 | 121.07 | 4,284.97 | 7,948.01 | 2,533.77 | 8,307.96 | 630.50 | 1,953.05 | 7,843.51 | 11,011.27 |
Altman Z-Score |
(10.16) | (13.63) | (8.62) | (12.08) | (6.28) | (4.39) | 27.42 | (4.42) | 3.31 | 9.41 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(24.85) | (33.14) | (21.46) | (35.02) | (19.22) | (29.56) | (14.75) | (7.81) | 1.04 | 10.17 |
P/Operating CF |
(25.88) | (20.97) | (23.12) | (21.02) | (33.03) | (87.26) | (13.14) | (6.54) | (25.88) | (45.06) |
Beneish M-Score |
4.57 | — | — | (0.13) | (2.30) | (2.95) | 37.85 | 3.82 | (4.07) | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.50 | 0.63 | 1.61 | 1.65 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.56 | 0.63 | 1.63 | 1.68 |
EV/Sales |
22.40 | 174.91 | 5,727.04 | 10,306.30 | 2,845.85 | 8,581.04 | 613.79 | 818.49 | 5,365.04 | 6,536.36 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(8.32) | (6.59) | (9.71) | (7.33) | (9.69) | (30.23) | (8.89) | (0.61) | (4.95) | (7.45) |
EV/FCF |
(8.22) | (6.48) | (8.97) | (5.66) | (9.23) | (29.94) | (8.65) | (0.51) | (2.89) | (6.37) |
Quick Ratio |
4.62 | 2.77 | 4.57 | 0.22 | 0.86 | 1.42 | 4.49 | 3.17 | 6.20 | 16.06 |
Current Ratio |
5.10 | 3.36 | 5.05 | 0.28 | 0.91 | 1.64 | 4.82 | 3.26 | 6.35 | 16.34 |
Net Debt/EBITDA |
(0.97) | (1.03) | (1.38) | (1.79) | (0.92) | (0.80) | 0.26 | 0.76 | 1.37 | 1.65 |
Debt/Assets |
95.06% | 120.62% | 135.10% | 185.78% | 129.79% | 118.02% | 10.37% | 3.80% | 0.94% | 0.81% |
Debt/Equity |
(0.95) | (0.95) | (1.16) | (1.50) | (2.50) | (2.20) | 0.12 | 0.05 | 0.01 | 0.01 |
Asset Turnover |
0.26 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.87 | 0.95 | 0.63 | 0.81 | 0.79 | 0.77 | 0.96 | 0.66 | 0.51 | 0.32 |
Capex/Depreciation |
(0.25) | (0.17) | (0.49) | (2.77) | (0.89) | (0.12) | (0.29) | (1.27) | (4.86) | (1.13) |
Interest Coverage |
(2.28) | (2.23) | (2.80) | (5.53) | (22.24) | (24.34) | (26.39) | (227.23) | (160.39) | (1,886.36) |
| 71.15% | 77.01% | 112.61% | 120.09% | 191.38% | (20,269.62%) | (118.32%) | (52.75%) | (37.65%) | (37.21%) | |
| (79.43%) | (93.21%) | (134.56%) | (100.22%) | (100.48%) | (121.73%) | (97.07%) | (44.51%) | (33.96%) | (35.31%) | |
ROIC |
0.00% | 0.00% | 0.00% | (189.00%) | (433.97%) | (295.46%) | (116.43%) | (78.07%) | (66.58%) | (80.17%) |
Return on Tangible Assets |
(95.65%) | (155.05%) | (152.72%) | 192.30% | (719.26%) | (191.05%) | (150.70%) | (69.53%) | (51.20%) | (57.12%) |
Average Days of Receivables |
137.16 | 58.42 | 0.00 | 2,874.38 | 520.93 | 312.51 | 50.22 | 94,496.17 | 10,203.78 | 22,132.27 |
Research and Development Expense of Revenue |
192.92% | 1,289.55% | 37,357.88% | 103,395.42% | 20,980.51% | 23,059.01% | 5,086.15% | 118,548.94% | 93,431.11% | 66,256.82% |
Selling, General and Administrative Expense of Revenue |
132.41% | 1,144.68% | 20,839.23% | 42,795.00% | 14,481.37% | 11,788.10% | 2,109.72% | 90,889.36% | 126,935.56% | 216,797.73% |
Intangible Assets out of Total Assets |
0.03 | 0.04 | 0.03 | 0.06 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.02 |
Share Based Compensation of Revenue |
32.49% | 233.52% | 7,904.02% | 16,741.25% | 6,122.16% | 361.49% | 155.36% | 49,748.94% | 82,215.56% | 167,845.45% |
Graham Net Nets |
(0.38) | (0.38) | (0.30) | (0.35) | (0.16) | (0.05) | 0.02 | 0.58 | 0.29 | 0.37 |
Graham Number |
2.15 | 3.07 | 5.48 | 5.15 | 3.56 | 2.05 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(19.19%) | (23.44%) | (22.14%) | (21.95%) | (14.75%) | (4.46%) | (18.73%) | (105.22%) | (27.40%) | (24.87%) |
Free Cash Flow Yield |
(16.95%) | (22.30%) | (14.91%) | (22.90%) | (12.17%) | (3.45%) | (11.25%) | (82.87%) | (23.68%) | (9.32%) |
Revenue per Share |
0.12 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.33) | (0.56) | (0.72) | (0.84) | (0.70) | (0.46) | (0.42) | (0.80) | (0.61) | (0.47) |
Capex per Share |
0.00 | (0.01) | (0.06) | (0.25) | (0.03) | 0.00 | (0.01) | (0.16) | (0.43) | (0.08) |
Free Cash Flow per Share |
(0.34) | (0.57) | (0.78) | (1.09) | (0.74) | (0.46) | (0.43) | (0.96) | (1.04) | (0.55) |
Cash per Share |
0.26 | 0.21 | 0.52 | 0.27 | 0.81 | 0.25 | 0.14 | 0.94 | 1.59 | 2.43 |
Shareholders Equity per Share |
(0.54) | (0.70) | (1.15) | (1.12) | (0.63) | (0.31) | 0.33 | 1.85 | 2.72 | 3.58 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.54) | (0.70) | (1.15) | (1.12) | (0.63) | (0.31) | 0.33 | 1.85 | 2.72 | 3.58 |
Free Cash Flow |
(308.78) | (398.12) | (397.34) | (436.90) | (287.48) | (173.39) | (156.20) | (76.07) | (83.59) | (45.15) |
Working Capital |
253.12 | 129.64 | 235.80 | (360.28) | (34.65) | 43.58 | 44.20 | 61.51 | 111.59 | 192.59 |
Capital Expenditures |
(3.85) | (6.89) | (30.58) | (99.39) | (13.06) | (1.67) | (4.09) | (12.69) | (34.81) | (6.56) |
Net Current Asset Value |
(686.60) | (686.48) | (796.30) | (671.60) | (378.48) | (228.16) | 33.31 | 52.83 | 100.86 | 181.07 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.47 | 49.17 | 414.13 | 13.99 | 2.76 | 1.86 | 270.00 | 773.67 | 149.09 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.14 | 0.29 | 0.42 | 0.25 | 0.18 | 0.19 | 0.23 | 0.13 | 0.09 | 0.31 |
Cash ROIC |
(140.14%) | (322.22%) | (109.74%) | (132.18%) | (42.17%) | (72.60%) | (83.45%) | (33.50%) | (23.93%) | (9.12%) |
Accounts Receivable Turnover |
5.04 | 6.94 | 0.00 | 0.15 | 1.01 | 1.47 | 0.35 | 0.01 | 0.02 | 0.03 |
Accounts Payable Turnover |
0.11 | 0.00 | 0.00 | 1.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.16 | — | — | 0.00 | — | — | — | — | — | — |
Average Days of Payables |
3,382.43 | 0.00 | 0.00 | 317.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
441.10 | 0.00 | — | 0.00 | — | — | — | — | — | — |
Average Receivables |
22.47 | 2.13 | — | 1.61 | 0.93 | 0.41 | 6.24 | 6.71 | 1.96 | 1.47 |
Average Payables |
6.85 | 7.96 | 15.11 | 16.22 | 11.46 | 6.63 | 2.27 | 4.33 | 4.96 | 3.07 |
Average Inventory |
4.59 | — | — | — | — | — | — | — | — | — |
Average Assets |
442.42 | 443.69 | 433.40 | 415.63 | 345.15 | 182.25 | 162.54 | 216.20 | 283.97 | 342.17 |
Average Common Equity |
(493.85) | (537.03) | (517.88) | (346.87) | (181.20) | 1.09 | 133.34 | 182.43 | 256.13 | 324.71 |
Columns are period end dates